Retatrutide
Triple GLP-1 / GIP / Glucagon Agonist$159 – $549
For Research Use Only. Not for human or veterinary use. Product strictly for laboratory research by qualified individuals. All sales are subject to our Terms & Conditions.
Prices are shown and charged in Canadian dollars (CAD).
Not from Canada? Your bank or payment provider will handle the exact exchange to your local currency automatically. Our currency switcher provides real-time USD estimates for reference only.
TrustLoop™
Partnership
We test, you test,
we reward.
Zero Risk
Protocol™
Purity guaranteed or your
money back. Full stop.
Complete Chain
of Custody
No dropshipping.
Full inventory control.
BATCH MATCHED
COAs
Every batch.
Every time.
cGMP & ISO 5
Benchmarks
Built for labs.
Grounded in protocol.
TrustLoop™
Partnership
We test, you test, we reward.
Zero Risk
Protocol™
Purity guaranteed or your money back.
Complete Chain
of Custody
No dropshipping. Full inventory control.
BATCH MATCHED
COAs
Every batch. Every time.
cGMP & ISO 5
Benchmarks
Built for labs. Grounded in protocol.
TrustLoop™
Partnership
We test and we reward.
Zero Risk
Protocol™
Money back guaruntee.
Complete Custody
Never dropshipped.
MATCHED
COAs
Every batch.
Every time.
cGMP & ISO 5
Benchmarks
Grounded in protocol.
Retatrutide is a synthetic triple agonist peptide targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously, representing the next generation of incretin-based research compounds beyond dual agonists. It is currently the subject of active Phase 3 clinical research, making it one of the most closely followed investigational peptides in the current pharmacological literature.
Researchers have investigated Retatrutide across a broad range of in vitro and in vivo models, with published Phase 1 and Phase 2 clinical trial data examining its simultaneous activation of all three incretin-related receptors and its interactions with glycaemic regulation, body weight modulation, and energy homeostasis pathways. Of particular interest to researchers is Retatrutide’s triple agonist mechanism, which published Phase 2 data suggests produces distinct and potentially additive metabolic effects compared to both selective GLP-1 agonists and dual GIP/GLP-1 agonists. Published research has further examined Retatrutide in models relating to insulin sensitivity, lipid metabolism, cardiovascular markers, and hepatic fat reduction pathways.
Ambros Labs supplies Retatrutide to qualified researchers across Canada from our Canadian inventory. Every batch is independently tested by a third-party Canadian laboratory using HPLC and mass spectrometry, with verifiable Certificates of Analysis available for every batch. All orders ship same-day from Canada with full chain of custody documentation.
For research use only. Not for human or veterinary use. For use by qualified researchers in appropriate laboratory settings only.
CAS Number: 2381089-83-2
Molecular Weight (g/moL): 4731.33
Molecular Formula: C221H342N46O68
Sequence: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-diacid-C20-γ-Glu-(AEEA)-Lys-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Format: White Lyophilized Powder
Related products
Semaglutide
$75 – $275